Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects
Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects
Moleculin與FDA修訂了其安那黴素與細胞苷聯合使用的第三階段臨床試驗協議；修訂後的協議加速了前45名受試者的初步主要療效數據及安全性/耐受性的揭盲。
Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects
Moleculin與FDA修訂了其安那黴素與細胞苷聯合使用的第三階段臨床試驗協議；修訂後的協議加速了前45名受試者的初步主要療效數據及安全性/耐受性的揭盲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間